Mayo Clinic
This phase III trial compares the effect of methylene blue mouthwash to standard of care mouthwash for the treatment of oral mucositis pain in patients with cancer. Using methlylene blue mouthwash may improve oral pain in patients with oral mucositis related to cancer and/or cancer treatments compared to usual standard of care.
Hematopoietic and Lymphoid System Neoplasm
Malignant Solid Neoplasm
Stomatitis
Anti-inflammatory/Antimicrobial/Analgesic Aqueous Mouth Rinse
Methylene Blue Oral Rinse
Phase 3
| Study Type : | Interventional |
| Estimated Enrollment : | 60 participants |
| Masking : | None (Open Label) |
| Primary Purpose : | Supportive Care |
| Official Title : | Methylene Blue Mouthwash for Oral Mucositis Pain in Cancer: An Open-Label, Non-Randomized, Controlled Study |
| Actual Study Start Date : | May 30, 2023 |
| Estimated Primary Completion Date : | December 2024 |
| Estimated Study Completion Date : | June 2025 |
| Arm | Intervention/treatment |
|---|---|
|
Active Comparator: Standard of Care Mouthwash Group Patients receive standard of care mouthwash as needed on study. |
Other: Anti-inflammatory/Antimicrobial/Analgesic Aqueous Mouth Rinse |
|
Experimental: Methylene Blue Mouthwash Group Patients receive Methylene Blue mouthwash as needed on study. |
Other: Methylene Blue Oral Rinse |
| Ages Eligible for Study: | 18 Years |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
Recruiting
Mayo Clinic in Rochester
Rochester, Minnesota, United States, 55905